Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease| (NASDAQ: AXSM) | Delayed: 207.78 -6.5 (3.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $214.28 | 52 Week High | $15.74 | |||
| Open | $212.05 | 52 Week Low | $5.37 | |||
| Day High | $213.27 | P/E | N/A | |||
| Day Low | $206.92 | EPS | $0.00 | |||
| Volume | 869,302 | |||||
